AegirBio (SUBGEN.ST) Stock Analysis & AI Equity Report
AegirBio (SUBGEN.ST) overview
AegirBio (SUBGEN.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, AegirBio reported revenue of SEK 204m and operating profit of SEK -129m; the year-end share price was 0.97 SEK and market capitalisation was SEK 0.1m. AegirBio is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get AegirBio's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About AegirBio
AegirBio AB is a Swedish diagnostics company that develops and commercializes tests and technology for monitoring biologic drug levels and other health conditions. Its portfolio has included laboratory, point-of-care, and home-testing products, as well as rapid tests, aimed at making diagnostics easier to use and providing quantitative results for clinical and self-monitoring applications.
Generate the AegirBio report
AegirBio is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for AegirBio and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on AegirBio
Each is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by what other analysts said the work added over the engine's report — a score out of five from people who had to read it to give it.